A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: Although most children with medulloblastoma are cured of their disease, Sonic Hedgehog (SHH) subgroup medulloblastoma driven by TRP53 mutations is essentially lethal. Casein kinase 1α (CK1α) phosphorylates and destabilizes GLI transcription factors, thereby inhibiting the key effectors of SHH signaling. We therefore tested a second-generation CK1α activator against TRP53-mutant, MYCN-amplified medulloblastoma. Experimental Design: The ability of this CK1α activator to block SHH signaling was determined in vitro using GLI reporter cells, granular precursor primary cultures, and PATCHED1 (PTCH1)-mutant sphere cultures. While in vivo efficacy was tested using 2 different medulloblastoma mouse models: PTCH1 and ND2:SMOA1. Finally, the clinical relevance of CK1α activators was demonstrated using a TRP53-mutant, MYCN-amplified patient-derived xenograft. Results: SSTC3 inhibited SHH activity in vitro, acting downstream of the vismodegib target SMOOTHENED (SMO), and reduced the viability of sphere cultures derived from SHH medulloblastoma. SSTC3 accumulated in the brain, inhibited growth of SHH medulloblastoma tumors, and blocked metastases in a genetically engineered vismodegib-resistant mouse model of SHH medulloblastoma. Importantly, SSTC3 attenuated growth and metastasis of orthotopic patient-derived TRP53-mutant, MYCN-amplified, SHH subgroup medulloblastoma xenografts, increasing overall survival. Conclusions: Using a newly described small-molecule, SSTC3, we show that CK1a activators could address a significant unmet clinical need for patients with SMO inhibitor–resistant medulloblastoma, including those harboring mutations in TRP53.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936 · cited 1×
“Comprehensive genomic and bioinformatic analysis has allowed MB to be stratified into four major subgroups, with distinct molecular drivers and prognoses(2, 3).”
BackgroundIntertumoral Heterogeneity within Medulloblastoma Subgroups
Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.005 · Cited by 1,219
Self-citationThe whole-genome landscape of medulloblastoma subtypes
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112
Rausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865
Svärd, J., Henricson, K. H., Persson-Lek, M., Rozell, B., Lauth, M., Bergström, Å., Ericson, J., Toftgård, R., & Teglund, S. (2006) · Developmental Cell · doi:10.1016/j.devcel.2005.12.013 · Cited by 468 · cited 1×
“PTCH1 (PTCH1/J(25)) or ND2: SMOA1 (C57BL/6-Tg(NEUROD2-SMO A1)199JOLS/J) mice (Jackson Laboratory) were mated to generate breeding colonies.”
BackgroundTargeting Transcription Factors in Cancer
Bhagwat, A. S., & Vakoc, C. R. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.001 · Cited by 276
Chen, Y., Sasai, N., Ma, G., Yue, T., Jia, J., Briscoe, J., & Jiang, J. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001083 · Cited by 225
Cited by
Targeting the Wnt/β-catenin signaling pathway in cancer
Zhang, Y., & Wang, X. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00990-3 · Cited by 1,431
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“SSTC3, a small molecule activator of CK1α, can inhibit the growth of heterologous transplants in CRC [321, 322].”
BackgroundWnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma
Lospinoso Severini, L., Ghirga, F., Bufalieri, F., Quaglio, D., Infante, P., & Di Marcotullio, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1823967 · Cited by 61
Molecular determinants of medulloblastoma metastasis and leptomeningeal dissemination
Li, M., Deng, Y., & Zhang, W. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-1026 · Cited by 37
Metadata
- Authors
- Rodriguez-Blanco, J., Li, B., Long, J., Shen, C., Yang, F., Orton, D., Collins, S., Kasahara, N., Ayad, N. G., McCrea, H. J., Roussel, M. F., Weiss, W. A., Capobianco, A. J., & Robbins, D. J.
- Venue
- Clinical Cancer Research
- Published
- 2019-02-15
- Volume
- 25
- Issue
- 4
- Pages
- 1379-1388
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2902688494
- Cited by
- 34
- References
- 7
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-1319
- The paper
- Rodriguez-Blanco, J., Li, B., Long, J., Shen, C., Yang, F., Orton, D., Collins, S., Kasahara, N., Ayad, N. G., McCrea, H. J., Roussel, M. F., Weiss, W. A., Capobianco, A. J., & Robbins, D. J. (2019). A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-1319
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.